Association between adjuvant therapy and survival in colorectal cancer patients according to metabolic Warburg-subtypes.

ABSTRACT:

Purpose

Tumor location and tumor node metastasis (TNM) stage guide treatment decisions in colorectal cancer (CRC) patients. However, patients with the same disease stage do not benefit equally from adjuvant therapy. Hence, there remains an urgent clinical need to identify prognostic and/or predictive biomarker(s) to personalize treatment decisions. In this exploratory study, we investigated whether our previously defined metabolic Warburg-subtypes can predict which CRC patients might derive survival benefit from adjuvant therapy.

Methods

Information regarding treatment (surgery only: n = 1451; adjuvant radiotherapy: n = 82; or adjuvant chemotherapy: n = 260) and Warburg-subtype (Warburg-low: n = 485, -moderate: n = 641, or -high: n = 667) was available for 1793 CRC patients

SUBMITTER: Offermans K 

PROVIDER: S-EPMC10356897 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature